Aytu BioPharma, Inc. (AYTU)

NASDAQ: AYTU · IEX Real-Time Price · USD
3.040
-0.040 (-1.30%)
Mar 28, 2024, 4:30 PM EDT - Market closed
-1.30%
Market Cap 16.93M
Revenue (ttm) 98.50M
Net Income (ttm) -18.00M
Shares Out 5.57M
EPS (ttm) -3.85
PE Ratio n/a
Forward PE 6.16
Dividend n/a
Ex-Dividend Date n/a
Volume 15,173
Open 3.100
Previous Close 3.080
Day's Range 3.011 - 3.120
52-Week Range 1.380 - 3.500
Beta -1.21
Analysts Strong Buy
Price Target 12.50 (+311.18%)
Earnings Date May 9, 2024

About AYTU

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric pres... [Read more]

Sector Healthcare
CEO Joshua R. Disbrow
Employees 150
Stock Exchange NASDAQ
Ticker Symbol AYTU
Full Company Profile

Financial Performance

In 2023, Aytu BioPharma's revenue was $107.40 million, an increase of 11.10% compared to the previous year's $96.67 million. Losses were -$17.05 million, -84.33% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 311.18% from the latest price.

Price Target
$12.5
(311.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted...

6 weeks ago - Accesswire

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its finan...

7 weeks ago - Accesswire

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Jo...

2 months ago - Accesswire

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Webcasted presentation to take place at 1:10pm ET DENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commerci...

4 months ago - Accesswire

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash ba...

4 months ago - Accesswire

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Ranked 118th Fastest Growing Company in North America Ranked 23rd Fastest Growing Life Sciences Company DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDA...

5 months ago - Accesswire

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial r...

5 months ago - Accesswire

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR...

5 months ago - Accesswire

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that ...

6 months ago - Accesswire

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA o...

6 months ago - Accesswire

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financ...

6 months ago - Accesswire

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced th...

7 months ago - Accesswire

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHD ENGLEWOOD, CO and...

8 months ago - Accesswire

Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufa...

9 months ago - Accesswire

Aytu to Participate in the Maxim Group Virtual Healthcare Conference

ENGLEWOOD, CO / ACCESSWIRE / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today an...

10 months ago - Accesswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Intere...

10 months ago - Accesswire

Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Intere...

10 months ago - Accesswire

Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results

Total prescriptions increased 32% compared to Q3 2022 to highest level in Company history Company to host conference call today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / May 11, 2023 / Aytu BioPharma,...

11 months ago - Accesswire

Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023

ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescri...

11 months ago - Accesswire

Aytu BioPharma Subleases a Portion of Its Manufacturing Facility

ENGLEWOOD, CO / ACCESSWIRE / May 1, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused presc...

11 months ago - Accesswire

Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer

U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023 Upon Completion of Manufacturing Transfer of Adzenys XR-OD...

1 year ago - Accesswire

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023

Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call Today at 5:00pm ET ENGLEWOOD, CO / ACCE...

1 year ago - Accesswire

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023

ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused p...

1 year ago - Accesswire

Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results

ENGLEWOOD, CO / ACCESSWIRE / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused p...

1 year ago - Accesswire

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023

ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused pr...

1 year ago - Accesswire